Label: PRAMIPEXOLE DIHYDROCHLORIDE- pramipexole dihydrochloride tablet

  • NDC Code(s): 0378-1704-05, 0378-1704-60, 0378-1704-77, 0378-1705-05, view more
    0378-1705-77, 0378-1707-05, 0378-1707-77, 0378-1711-05, 0378-1711-77, 0378-1712-05, 0378-1712-77, 0378-1713-05, 0378-1713-77
  • Packager: Mylan Pharmaceuticals Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated 04/15

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use pramipexole dihydrochloride tablets safely and effectively. See full prescribing information for pramipexole dihydrochloride tablets.

    PRAMIPEXOLE dihydrochloride tablets, for oral use
    Initial U.S. Approval: 1997

    RECENT MAJOR CHANGES

    Warnings and Precautions: Hallucinations and Psychotic-like Behavior (5.4)     4/2015

    Warnings and Precautions: Events Reported with Dopaminergic Therapy (5.9)     4/2015

    INDICATIONS AND USAGE

    Pramipexole is a non-ergot dopamine agonist indicated for the treatment of:

    Parkinson’s disease (PD) ( 1.1)

    DOSAGE AND ADMINISTRATION

    *
    Doses should not be increased more frequently than every 5 to 7 days. Titrate to effective dose. If used with levodopa, may need to reduce levodopa dose.

    Parkinson’s Disease-Normal Renal Function* (2.2)

    Week

    Dosage (mg)

    Total Daily Dose (mg)

    1

    0.125 TID

    0.375

    2

    0.25 TID

    0.75

    3

    0.5 TID

    1.5

    4

    0.75 TID

    2.25

    5

    1 TID

    3

    6

    1.25 TID

    3.75

    7

    1.5 TID

    4.5

    Parkinson’s Disease-Impaired Renal Function (2.2)

    Creatinine Clearance

    Starting Dose (mg)

    Maximum Dose (mg)

    > 50 mL/min

    0.125 TID

    1.5 TID

    30 to 50 mL/min

    0.125 BID

    0.75 TID

    15 to 30 mL/min

    0.125 QD

    1.5 QD

    < 15 mL/min and hemodialysis patients

    Data not available

    DOSAGE FORMS AND STRENGTHS

    Tablets: 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg and 1.5 mg (3)

    CONTRAINDICATIONS

    None (4)

    WARNINGS AND PRECAUTIONS

    Falling asleep during activities of daily living: Sudden onset of sleep may occur without warning; advise patients to report symptoms ( 5.1)
    Symptomatic orthostatic hypotension. Monitor during dose escalation ( 5.2)
    Impulse control/Compulsive behaviors: Patients may experience compulsive behaviors and other intense urges ( 5.3)
    Hallucinations and Psychotic-like behavior: May occur; risk increases with age ( 5.4)
    Dyskinesia: May be caused or exacerbated by pramipexole ( 5.5)
    Events reported with dopaminergic therapy: Include hyperpyrexia and confusion, fibrotic complications, and melanoma ( 5.9)

    ADVERSE REACTIONS

    Most common adverse reactions (incidence > 5% and greater than placebo):

    Early PD without levodopa: nausea, dizziness, somnolence, insomnia, constipation, asthenia, and hallucinations ( 6.1)
    Advanced PD with levodopa: postural (orthostatic) hypotension, dyskinesia, extrapyramidal syndrome, insomnia, dizziness, hallucinations, accidental injury, dream abnormalities, confusion, constipation, asthenia, somnolence, dystonia, gait abnormality, hypertonia, dry mouth, amnesia, and urinary frequency ( 6.1)

    To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    Dopamine Antagonists: May diminish the effectiveness of pramipexole (7.1).

    USE IN SPECIFIC POPULATIONS

    Pregnancy: Based on animal data, may cause fetal harm (8.1)

    See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

    Revised: 4/2015

    Close
  • FULL PRESCRIBING INFORMATION: CONTENTS*
  • 1 INDICATIONS AND USAGE

    1.1 Parkinson’s Disease

    Pramipexole dihydrochloride tablets are indicated for the treatment of Parkinson's disease.

    Close
  • 2 DOSAGE AND ADMINISTRATION

    2.1 General Dosing Considerations

    Pramipexole dihydrochloride tablets are taken orally, with or without food.

    If a significant interruption in therapy with pramipexole dihydrochloride tablets has occurred, re-titration of therapy may be warranted.

    2.2 Dosing for Parkinson's Disease

    In all clinical studies, dosage was initiated at a subtherapeutic level to avoid intolerable adverse effects and orthostatic hypotension. Pramipexole dihydrochloride tablets should be titrated gradually in all patients. The dose should be increased to achieve a maximum therapeutic effect, balanced against the principal side effects of dyskinesia, hallucinations, somnolence, and dry mouth.

    Dosing in Patients with Normal Renal Function

    Initial Treatment

    Doses should be increased gradually from a starting dose of 0.375 mg/day given in three divided doses and should not be increased more frequently than every 5 to 7 days. A suggested ascending dosage schedule that was used in clinical studies is shown in Table 1.

    Table 1: Ascending Dosage Schedule of Pramipexole Dihydrochloride Tablets for Parkinson’s Disease

    Week

    Dosage (mg)

    Total Daily Dose (mg)

    1

    0.125 three times a day

    0.375

    2

    0.25 three times a day

    0.75

    3

    0.5 three times a day

    1.50

    4

    0.75 three times a day

    2.25

    5

    1 three times a day

    3

    6

    1.25 three times a day

    3.75

    7

    1.5 three times a day

    4.50

    Maintenance Treatment

    Pramipexole dihydrochloride tablets were effective and well tolerated over a dosage range of 1.5 to 4.5 mg/day administered in equally divided doses 3 times per day with or without concomitant levodopa (approximately 800 mg/day).

    In a fixed-dose study in early Parkinson's disease patients, doses of 3 mg, 4.5 mg, and 6 mg per day of pramipexole dihydrochloride tablets were not shown to provide any significant benefit beyond that achieved at a daily dose of 1.5 mg/day. However, in the same fixed-dose study, the following adverse events were dose related: postural hypotension, nausea, constipation, somnolence, and amnesia. The frequency of these events was generally 2-fold greater than placebo for pramipexole doses greater than 3 mg/day. The incidence of somnolence reported with pramipexole at a dose of 1.5 mg/day was comparable to placebo.

    When pramipexole dihydrochloride tablets are used in combination with levodopa, a reduction of the levodopa dosage should be considered. In a controlled study in advanced Parkinson's disease, the dosage of levodopa was reduced by an average of 27% from baseline.

    Dosing in Patients with Renal Impairment

    The recommended dosing of pramipexole dihydrochloride tablets in Parkinson’s disease patients with renal impairment is provided in Table 2.

    Table 2 Dosing of Pramipexole Dihydrochloride Tablets in Parkinson’s Disease Patients with Renal Impairment

    Renal Status

    Starting Dose (mg)

    Maximum Dose (mg)

    Normal to Mild Impairment
    (creatinine Cl > 50 mL/min)

    0.125 three times a day

    1.5 three times a day

    Moderate Impairment
    (creatinine Cl = 30 to 50 mL/min)

    0.125 twice a day

    0.75 three times a day

    Severe Impairment
    (creatinine Cl = 15 to < 30 mL/min)

    0.125 once a day

    1.5 once a day

    Very Severe Impairment
    (creatinine Cl < 15 mL/min and hemodialysis patients)

    The use of pramipexole dihydrochloride tablets has not been adequately studied in this group of patients.

    Discontinuation of Treatment

    Pramipexole dihydrochloride tablets may be tapered off at a rate of 0.75 mg per day until the daily dose has been reduced to 0.75 mg. Thereafter, the dose may be reduced by 0.375 mg per day.

    Close
  • 3 DOSAGE FORMS AND STRENGTHS

    0.125 mg: white to off-white round, unscored tablets debossed with M on one side of the tablet and X4 on the other side
    0.25 mg: light orange round tablets debossed with M on one side of the tablet and X to the left of the score and 5 to the right of the score on the other side.
    0.5 mg: light blue round tablets debossed with M on one side of the tablet and X to the left of the score and 7 to the right of the score on the other side.
    0.75 mg: light gray round, unscored tablets debossed with M on one side of the tablet and X13 on the other side.
    1 mg: beige round tablets debossed with M on one side of the tablet and X to the left of the score and 11 to the right of the score on the other side.
    1.5 mg: light lavender round tablets debossed with M on one side of the tablet and X to the left of the score and 12 to the right of the score on the other side.
    Close
  • 4 CONTRAINDICATIONS

    None.

    Close
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Falling Asleep During Activities of Daily Living and Somnolence

    Patients treated with pramipexole have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles which sometimes resulted in accidents. Although many of these patients reported somnolence while on pramipexole tablets, some perceived that they had no warning signs (sleep attack) such as excessive drowsiness, and believed that they were alert immediately prior to the event. Some of these events had been reported as late as one year after the initiation of treatment.

    Somnolence is a common occurrence in patients receiving pramipexole at doses above 1.5 mg/day (0.5 mg three times a day) for Parkinson’s disease. It has been reported that falling asleep while engaged in activities of daily living usually occurs in a setting of pre-existing somnolence, although patients may not give such a history. For this reason, prescribers should reassess patients for drowsiness or sleepiness, especially since some of the events occur well after the start of treatment. Prescribers should also be aware that patients may not acknowledge drowsiness or sleepiness until directly questioned about drowsiness or sleepiness during specific activities.

    Before initiating treatment with pramipexole, advise patients of the potential to develop drowsiness and specifically asked about factors that may increase the risk for somnolence with pramipexole such as the use of concomitant sedating medications or alcohol, the presence of sleep disorders, and concomitant medications that increase pramipexole plasma levels (e.g., cimetidine) [see Clinical Pharmacology (12.3)]. If a patient develops significant daytime sleepiness or episodes of falling asleep during activities that require active participation (e.g., conversations, eating, etc.), pramipexole should ordinarily be discontinued. If a decision is made to continue pramipexole, advise patients not to drive and to avoid other potentially dangerous activities that might result in harm if the patients become somnolent. While dose reduction reduces the degree of somnolence, there is insufficient information to establish that dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living.

    5.2 Symptomatic Orthostatic Hypotension

    Dopamine agonists, in clinical studies and clinical experience, appear to impair the systemic regulation of blood pressure, with resulting orthostatic hypotension, especially during dose escalation. Parkinson's disease patients, in addition, appear to have an impaired capacity to respond to an orthostatic challenge. For these reasons, Parkinson's disease patients being treated with dopaminergic agonists ordinarily require careful monitoring for signs and symptoms of orthostatic hypotension, especially during dose escalation, and should be informed of this risk.

    In clinical trials of pramipexole, however, and despite clear orthostatic effects in normal volunteers, the reported incidence of clinically significant orthostatic hypotension was not greater among those assigned to pramipexole tablets than among those assigned to placebo. This result, especially with the higher doses used in Parkinson’s disease, is clearly unexpected in light of the previous experience with the risks of dopamine agonist therapy.

    While this finding could reflect a unique property of pramipexole, it might also be explained by the conditions of the study and the nature of the population enrolled in the clinical trials. Patients were very carefully titrated, and patients with active cardiovascular disease or significant orthostatic hypotension at baseline were excluded.

    5.3 Impulse Control/Compulsive Behaviors

    Case reports and the results of a cross-sectional study suggest that patients can experience intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, binge eating, and/or other intense urges and the inability to control these urges while taking one or more of the medications, including pramipexole, that increase central dopaminergic tone and that are generally used for the treatment of Parkinson’s disease. In some cases, although not all, these urges were reported to have stopped when the dose was reduced or the medication was discontinued. Because patients may not recognize these behaviors as abnormal it is important for prescribers to specifically ask patients or their caregivers about the development of new or increased gambling urges, sexual urges, uncontrolled spending or other urges while being treated with pramipexole. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking pramipexole.

    5.4 Hallucinations and Psychotic-like Behavior

    In the three double-blind, placebo-controlled trials in early Parkinson's disease, hallucinations were observed in 9% (35 of 388) of patients receiving pramipexole, compared with 2.6% (6 of 235) of patients receiving placebo. In the four double-blind, placebo-controlled trials in advanced Parkinson's disease, where patients received pramipexole and concomitant levodopa, hallucinations were observed in 16.5% (43 of 260) of patients receiving pramipexole compared with 3.8% (10 of 264) of patients receiving placebo. Hallucinations were of sufficient severity to cause discontinuation of treatment in 3.1% of the early Parkinson's disease patients and 2.7% of the advanced Parkinson's disease patients compared with about 0.4% of placebo patients in both populations.

    Age appears to increase the risk of hallucinations attributable to pramipexole. In the early Parkinson's disease patients, the risk of hallucinations was 1.9 times greater than placebo in patients younger than 65 years and 6.8 times greater than placebo in patients older than 65 years. In the advanced Parkinson's disease patients, the risk of hallucinations was 3.5 times greater than placebo in patients younger than 65 years and 5.2 times greater than placebo in patients older than 65 years.

    Postmarketing reports with medication used to treat Parkinson’s disease, including pramipexole, indicate that patients may experience new or worsening mental status and behavioral changes, which may be severe, including psychotic-like behavior during treatment with pramipexole or after starting or increasing the dose of pramipexole. Other drugs prescribed to improve the symptoms of Parkinson’s disease can have similar effects on thinking and behavior. This abnormal thinking and behavior can consist of one or more of a variety of manifestations including paranoid ideation, delusions, hallucinations, confusion, psychotic-like behavior, disorientation, aggressive behavior, agitation, and delirium.

    Patients with a major psychotic disorder should ordinarily not be treated with dopamine agonists, including pramipexole, because of the risk of exacerbating the psychosis. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson’s disease and may decrease the effectiveness of pramipexole [see Drug Interactions (7.1)].

    5.5 Dyskinesia

    Pramipexole may potentiate the dopaminergic side effects of levodopa and may cause or exacerbate preexisting dyskinesia.

    5.6 Renal Impairment

    Since pramipexole is eliminated through the kidneys, caution should be exercised when prescribing pramipexole to patients with renal impairment [see Dosage and Administration (2), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].

    5.7 Rhabdomyolysis

    A single case of rhabdomyolysis occurred in a 49-year-old male with advanced Parkinson's disease treated with pramipexole. The patient was hospitalized with an elevated CPK (10,631 IU/L). The symptoms resolved with discontinuation of the medication.

    5.8 Retinal Pathology

    Human Data

    A 2-year open-label, randomized, parallel-group safety study of retinal deterioration and vision compared pramipexole tablets and immediate-release ropinirole. Two hundred thirty four Parkinson’s disease patients (115 on pramipexole, mean dose 3 mg/day and 119 on ropinirole, mean dose 9.5 mg/day) were evaluated using a panel of clinical ophthalmological assessments. Of 234 patients who were evaluable, 196 had been treated for 2 years and 29 were judged to have developed clinical abnormalities that were considered meaningful (19 patients in each treatment arm had received treatment for less than 2 years). There was no statistical difference in retinal deterioration between the treatment arms; however, the study was only capable of detecting a very large difference between treatments. In addition, because the study did not include an untreated comparison group (placebo treated), it is unknown whether the findings reported in patients treated with either drug are greater than the background rate in an aging population.

    Animal Data

    Pathologic changes (degeneration and loss of photoreceptor cells) were observed in the retina of albino rats in the 2-year carcinogenicity study. While retinal degeneration was not diagnosed in pigmented rats treated for 2 years, a thinning in the outer nuclear layer of the retina was slightly greater in rats given drug compared with controls. Evaluation of the retinas of albino mice, monkeys, and minipigs did not reveal similar changes. The potential significance of this effect in humans has not been established, but cannot be disregarded because disruption of a mechanism that is universally present in vertebrates (i.e., disk shedding) may be involved [see Nonclinical Toxicology (13.2)].

    5.9 Events Reported with Dopaminergic Therapy

    Although the events enumerated below may not have been reported in association with the use of pramipexole in its development program, they are associated with the use of other dopaminergic drugs. The expected incidence of these events, however, is so low that even if pramipexole caused these events at rates similar to those attributable to other dopaminergic therapies, it would be unlikely that even a single case would have occurred in a cohort of the size exposed to pramipexole in studies to date.

    Hyperpyrexia and Confusion

    Although not reported with pramipexole in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. If possible, avoid sudden discontinuation or rapid dose reduction in patients taking pramipexole tablets. If the decision is made to discontinue pramipexole tablets, the dose should be tapered to reduce the risk of hyperpyrexia and confusion [see Dosage and Administration (2.2)].

    Fibrotic Complications

    Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in patients treated with ergot-derived dopaminergic agents. While these complications may resolve when the drug is discontinued, complete resolution does not always occur.

    Although these adverse events are believed to be related to the ergoline structure of these compounds, whether other, nonergot-derived dopamine agonists can cause them is unknown.

    Cases of possible fibrotic complications, including peritoneal fibrosis, pleural fibrosis, and pulmonary fibrosis have been reported in the post marketing experience with pramipexole. While the evidence is not sufficient to establish a causal relationship between pramipexole and these fibrotic complications, a contribution of pramipexole cannot be completely ruled out.

    Melanoma

    Epidemiological studies have shown that patients with Parkinson’s disease have a higher risk (2- to approximately 6-fold higher) of developing melanoma than the general population. Whether the observed increased risk was due to Parkinson’s disease or other factors, such as drugs used to treat Parkinson’s disease, is unclear.

    For the reasons stated above, patients and providers are advised to monitor for melanomas frequently and on a regular basis when using pramipexole for any indication. Ideally, periodic skin examinations should be performed by appropriately qualified individuals (e.g., dermatologists).

    Close
  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed in greater detail in other sections of the labeling:

    Falling Asleep During Activities of Daily Living and Somnolence [see Warnings and Precautions (5.1)].
    Symptomatic Orthostatic Hypotension [see Warnings and Precautions (5.2)].
    Impulse Control/Compulsive Behaviors [see Warnings and Precautions (5.3)].
    Hallucinations and Psychotic-like Behavior [see Warnings and Precautions (5.4)].
    Dyskinesia [see Warnings and Precautions (5.5)].
    Rhabdomyolysis [see Warnings and Precautions (5.7)].
    Retinal Pathology [see Warnings and Precautions (5.8)].
    Events Reported with Dopaminergic Therapy [see Warnings and Precautions (5.9)].

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

    Parkinson's Disease

    During the premarketing development of pramipexole, patients with either early or advanced Parkinson's disease were enrolled in clinical trials. Apart from the severity and duration of their disease, the two populations differed in their use of concomitant levodopa therapy. Patients with early disease did not receive concomitant levodopa therapy during treatment with pramipexole; those with advanced Parkinson's disease all received concomitant levodopa treatment. Because these two populations may have differential risks for various adverse reactions, this section will, in general, present adverse-reaction data for these two populations separately.

    Because the controlled trials performed during premarketing development all used a titration design, with a resultant confounding of time and dose, it was impossible to adequately evaluate the effects of dose on the incidence of adverse reactions.

    Early Parkinson's Disease

    In the three double-blind, placebo-controlled trials of patients with early Parkinson's disease, the most common adverse reactions (> 5%) that were numerically more frequent in the group treated with pramipexole were nausea, dizziness, somnolence, insomnia, constipation, asthenia, and hallucinations.

    Approximately 12% of 388 patients with early Parkinson's disease and treated with pramipexole who participated in the double-blind, placebo-controlled trials discontinued treatment due to adverse reactions compared with 11% of 235 patients who received placebo. The adverse reactions most commonly causing discontinuation of treatment were related to the nervous system (hallucinations [3.1% on pramipexole vs. 0.4% on placebo]; dizziness [2.1% on pramipexole vs. 1% on placebo]; somnolence [1.6% on pramipexole vs. 0% on placebo]; headache and confusion [1.3% and 1%, respectively, on pramipexole vs. 0% on placebo]); and gastrointestinal system (nausea [2.1% on pramipexole vs. 0.4% on placebo]).

    Adverse Reaction Incidence in Controlled Clinical Studies in Early Parkinson's Disease

    Table 3 lists adverse reactions that occurred in the double-blind, placebo-controlled studies in early Parkinson's disease that were reported by ≥ 1% of patients treated with pramipexole and were numerically more frequent than in the placebo group. In these studies, patients did not receive concomitant levodopa.

    Table 3: Adverse-Reactions in Pooled Double-Blind, Placebo-Controlled Trials with Pramipexole in Early Parkinson's Disease

    Body System/Adverse Reaction

    Pramipexole

    (N = 388)

    %

    Placebo

    (N = 235)

    %

    Nervous System

     
         Dizziness

    25

    24

     
         Somnolence

    22

    9

     
         Insomnia

    17

    12

     
         Hallucinations

    9

    3

     
         Confusion

    4

    1

     
         Amnesia

    4

    2

     
         Hypesthesia

    3

    1

     
         Dystonia

    2

    1

     
         Akathisia

    2

    0

     
         Thinking abnormalities

    2

    0

     
         Decreased libido

    1

    0

     
         Myoclonus

    1

    0

    Digestive System

     
         Nausea

    28

    18

     
         Constipation

    14

    6

     
         Anorexia

    4

    2

     
         Dysphagia

    2

    0

    Body as a Whole

     
         Asthenia

    14

    12

     
         General edema

    5

    3

     
         Malaise

    2

    1

     
         Reaction unevaluable

    2

    1

     
         Fever

    1

    0

    Metabolic & Nutritional System

     
         Peripheral edema

    5

    4

     
         Decreased weight

    2

    0

    Special Senses

     
         Vision abnormalities

    3

    0

    Urogenital System

     
         Impotence

    2

    1

    In a fixed-dose study in early Parkinson's disease, occurrence of the following reactions increased in frequency as the dose increased over the range from 1.5 mg/day to 6 mg/day: postural hypotension, nausea, constipation, somnolence, and amnesia. The frequency of these reactions was generally 2-fold greater than placebo for pramipexole doses greater than 3 mg/day. The incidence of somnolence with pramipexole at a dose of 1.5 mg/day was comparable to that reported for placebo.

    Advanced Parkinson's Disease

    In the four double-blind, placebo-controlled trials of patients with advanced Parkinson's disease, the most common adverse reactions (> 5%) that were numerically more frequent in the group treated with pramipexole and concomitant levodopa were postural (orthostatic) hypotension, dyskinesia, extrapyramidal syndrome, insomnia, dizziness, hallucinations, accidental injury, dream abnormalities, confusion, constipation, asthenia, somnolence, dystonia, gait abnormality, hypertonia, dry mouth, amnesia, and urinary frequency.

    Approximately 12% of 260 patients with advanced Parkinson's disease who received pramipexole and concomitant levodopa in the double-blind, placebo-controlled trials discontinued treatment due to adverse reactions compared with 16% of 264 patients who received placebo and concomitant levodopa. The reactions most commonly causing discontinuation of treatment were related to the nervous system (hallucinations [2.7% on pramipexole vs. 0.4% on placebo]; dyskinesia [1.9% on pramipexole vs. 0.8% on placebo]); and cardiovascular system (postural [orthostatic] hypotension [2.3% on pramipexole vs. 1.1% on placebo]).

    Adverse Reaction Incidence in Controlled Clinical Studies in Advanced Parkinson's Disease

    Table 4 lists adverse reactions that occurred in the double-blind, placebo-controlled studies in advanced Parkinson's disease that were reported by ≥ 1% of patients treated with pramipexole and were numerically more frequent than in the placebo group. In these studies, pramipexole or placebo was administered to patients who were also receiving concomitant levodopa.

    Table 4: Adverse Reactions in Pooled Double-Blind, Placebo-Controlled Trials with Pramipexole in Advanced Parkinson's Disease

    Body System/Adverse Reaction

    Pramipexole

    (N = 260)

    %

    Placebo

    (N = 264)

    %

    Nervous System

     
         Dyskinesia

    47

    31

     
         Extrapyramidal syndrome

    28

    26

     
         Insomnia

    27

    22

     
         Dizziness

    26

    25

     
         Hallucinations

    17

    4

     
         Dream abnormalities

    11

    10

     
         Confusion

    10

    7

     
         Somnolence

    9

    6

     
         Dystonia

    8

    7

     
         Gait abnormalities

    7

    5

     
         Hypertonia

    7

    6

     
         Amnesia

    6

    4

     
         Akathisia

    3

    2

     
         Thinking abnormalities

    3

    2

     
         Paranoid reaction

    2

    0

     
         Delusions

    1

    0

     
         Sleep disorders

    1

    0

    Cardiovascular System

     
         Postural hypotension

    53

    48

    Body as a Whole

     
         Accidental injury

    17

    15

     
         Asthenia

    10

    8

     
         General edema

    4

    3

     
         Chest pain

    3

    2

     
         Malaise

    3

    2

    Digestive System

     
         Constipation

    10

    9

     
         Dry mouth

    7

    3

    Urogenital System

     
         Urinary frequency

    6

    3

     
         Urinary tract infection

    4

    3

     
         Urinary incontinence

    2

    1

    Respiratory System

     
         Dyspnea

    4

    3

     
         Rhinitis

    3

    1

     
         Pneumonia

    2

    0

    Special Senses

     
         Accommodation abnormalities

    4

    2

     
         Vision abnormalities

    3

    1

     
         Diplopia

    1

    0

    Musculoskeletal System

     
         Arthritis

    3

    1

     
         Twitching

    2

    0

     
         Bursitis

    2

    0

     
         Myasthenia

    1

    0

    Metabolic & Nutritional System

     
         Peripheral edema

    2

    1

     
         Increased creatine PK

    1

    0

    Skin & Appendages

     
         Skin disorders

    2

    1

    Adverse Reactions; Relationship to Age, Gender and Race

    Among the adverse reactions in patients treated with pramipexole, hallucination appeared to exhibit a positive relationship to age in patients with Parkinson’s disease. No gender-related differences were observed in Parkinson’s disease patients. Less than 4% of patients enrolled were non-Caucasian: therefore, an evaluation of adverse reactions related to race is not possible.

    Laboratory Tests

    During the development of pramipexole, no systematic abnormalities on routine laboratory testing were noted.

    6.2 Post Marketing Experience

    In addition to the adverse events reported during clinical trials, the following adverse reactions have been identified during post-approval use of pramipexole, primarily in Parkinson’s disease patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to pramipexole tablets. Similar types of reactions were grouped into a smaller number of standardized categories using the MedDRA terminology: cardiac failure, inappropriate antidiuretic hormone secretion (SIADH), syncope, vomiting, and weight increase.

    Close
  • 7 DRUG INTERACTIONS

    7.1 Dopamine Antagonists

    Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of pramipexole.

    Close
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Teratogenic Effects. Pregnancy Category C

    There are no adequate and well-controlled studies in pregnant women. Pramipexole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    When pramipexole was given to female rats throughout pregnancy, implantation was inhibited at a dose of 2.5 mg/kg/day (5 times the maximum recommended human dose (MRHD) for Parkinson’s disease of 4.5 mg/day on a body surface area (mg/m2) basis). Administration of 1.5 mg/kg/day of pramipexole to pregnant rats during the period of organogenesis (gestation days 7 through 16) resulted in a high incidence of total resorption of embryos. The plasma AUC in rats at this dose was 4 times the AUC in humans at the MRHD. These findings are thought to be due to the prolactin-lowering effect of pramipexole, since prolactin is necessary for implantation and maintenance of early pregnancy in rats (but not rabbits or humans). Because of pregnancy disruption and early embryonic loss in these studies, the teratogenic potential of pramipexole could not be adequately evaluated. There was no evidence of adverse effects on embryo-fetal development following administration of up to 10 mg/kg/day to pregnant rabbits during organogenesis (plasma AUC was 70 times that in humans at the MRHD). Postnatal growth was inhibited in the offspring of rats treated with 0.5 mg/kg/day (approximately equivalent to the MRHD on a mg/m2 basis) or greater during the latter part of pregnancy and throughout lactation.

    8.3 Nursing Mothers

    Studies have shown that pramipexole treatment resulted in an inhibition of prolactin secretion in humans and rats.

    A single-dose, radio-labeled study showed that drug-related material was present in rat milk at concentrations 3 to 6 times higher than those in plasma at equivalent time points. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from pramipexole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

    8.4 Pediatric Use

    Safety and effectiveness of pramipexole in pediatric patients has not been established.

    8.5 Geriatric Use

    Pramipexole total oral clearance is approximately 30% lower in subjects older than 65 years compared with younger subjects, because of a decline in pramipexole renal clearance due to an age-related reduction in renal function. This resulted in an increase in elimination half-life from approximately 8.5 hours to 12 hours.

    In clinical studies with Parkinson’s disease patients, 38.7% of patients were older than 65 years. There were no apparent differences in efficacy or safety between older and younger patients, except that the relative risk of hallucination associated with the use of pramipexole was increased in the elderly.

    8.6 Renal Impairment

    The elimination of pramipexole is dependent on renal function. Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of pramipexole is removed by dialysis. Caution should be exercised when administering pramipexole to patients with renal disease [see Dosage and Administration (2.2), Warnings and Precautions (5.6), and Clinical Pharmacology (12.3)].

    Close
  • 10 OVERDOSAGE

    There is no clinical experience with significant overdosage. One patient took 11 mg/day of pramipexole for 2 days in a clinical trial for an investigational use. Blood pressure remained stable although pulse rate increased to between 100 and 120 beats/minute. No other adverse reactions were reported related to the increased dose.

    There is no known antidote for overdosage of a dopamine agonist. If signs of central nervous system stimulation are present, a phenothiazine or other butyrophenone neuroleptic agent may be indicated; the efficacy of such drugs in reversing the effects of overdosage has not been assessed. Management of overdose may require general supportive measures along with gastric lavage, intravenous fluids, and electrocardiogram monitoring.

    Close
  • 11 DESCRIPTION

    Pramipexole dihydrochloride tablets contain pramipexole, a nonergot dopamine agonist. The chemical name of pramipexole dihydrochloride is (S)-2-amino-4,5,6,7- tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate. Its molecular formula is C10H17N3S·2HCl·H2O, and its molecular weight is 302.27. The structural formula is:

    Pramipexole Dihydrochloride Structural Formula

    Pramipexole dihydrochloride, USP is a white to off-white crystalline powder. Melting occurs in the range of 296°C to 301°C, with decomposition. Pramipexole dihydrochloride is more than 20% soluble in water, about 8% in methanol, about 0.5% in ethanol, and practically insoluble in dichloromethane.

    Pramipexole dihydrochloride tablets, for oral administration, contain 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg or 1.5 mg of pramipexole dihydrochloride, USP. Inactive ingredients consist of colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, magnesium stearate, mannitol, pregelatinized starch (corn) and sodium citrate. In addition, the following product specific coloring agents are present:

    0.25 mg contains FD&C Yellow No. 6 Aluminum Lake.

    0.5 mg contains FD&C Yellow No. 6 Aluminum Lake and FD&C Blue No. 2 Aluminum Lake.

    0.75 mg contains FD&C Yellow No. 6 Aluminum Lake and FD&C Blue No. 2 Aluminum Lake.

    1 mg contains FD&C Yellow No. 6 Aluminum Lake and FD&C Blue No. 2 Aluminum Lake.

    1.5 mg contains FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake and D&C Red No. 27 Aluminum Lake.

    Close
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Pramipexole is a non-ergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes.

    Parkinson’s Disease

    The precise mechanism of action of pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum. The relevance of D3 receptor binding in Parkinson’s disease is unknown.

    12.2 Pharmacodynamics

    The effect of pramipexole on the QT interval of the ECG was investigated in a clinical study in 60 healthy male and female volunteers. All subjects initiated treatment with 0.375 mg extended release pramipexole tablets administered once daily, and were up-titrated every 3 days to 2.25 mg and 4.5 mg daily, a faster rate of titration than recommended in the label. No dose- or exposure-related effect on mean QT intervals was observed; however the study did not have a valid assessment of assay sensitivity. The effect of pramipexole on QTc intervals at higher exposures achieved either due to drug interactions (e.g., with cimetidine), renal impairment, or at higher doses has not been systematically evaluated.

    Although mean values remained within normal reference ranges throughout the study, supine systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse rate for subjects treated with pramipexole generally increased during the rapid up-titration phase, by 10 mmHg, 7 mmHg, and 10 bpm higher than placebo, respectively. Higher SBP, DBP, and pulse rates compared to placebo were maintained until the pramipexole doses were tapered; values on the last day of tapering were generally similar to baseline values. Such effects have not been observed in clinical studies with Parkinson’s disease patients, who were titrated according to labeled recommendations.

    12.3 Pharmacokinetics

    Pramipexole displays linear pharmacokinetics over the clinical dosage range. Its terminal half-life is about 8 hours in young healthy volunteers and about 12 hours in elderly volunteers. Steady-state concentrations are achieved within 2 days of dosing.

    Absorption

    Pramipexole is rapidly absorbed, reaching peak concentrations in approximately 2 hours. The absolute bioavailability of pramipexole is greater than 90%, indicating that it is well absorbed and undergoes little presystemic metabolism. Food does not affect the extent of pramipexole absorption, although the time of maximum plasma concentration (Tmax) is increased by about one hour when the drug is taken with a meal.

    Distribution

    Pramipexole is extensively distributed, having a volume of distribution of about 500 L (coefficient of variation [CV] = 20%). It is about 15% bound to plasma proteins. Pramipexole distributes into red blood cells as indicated by an erythrocyte-to-plasma ratio of approximately 2.

    Metabolism

    Pramipexole is metabolized only to a negligible extent (< 10%). No specific active metabolite has been identified in human plasma or urine.

    Elimination

    Urinary excretion is the major route of pramipexole elimination, with 90% of a pramipexole dose recovered in urine, almost all as unchanged drug. The renal clearance of pramipexole is approximately 400 mL/min (CV = 25%), approximately 3 times higher than the glomerular filtration rate. Thus, pramipexole is secreted by the renal tubules, probably by the organic cation transport system.

    Pharmacokinetics in Specific Populations

    Because therapy with pramipexole is initiated at a low dose and gradually titrated upward according to clinical tolerability to obtain the optimum therapeutic effect, adjustment of the initial dose based on gender, weight, race, or age is not necessary. However, renal insufficiency, which can cause a large decrease in the ability to eliminate pramipexole, may necessitate dosage adjustment [see Dosage and Administration (2.2)].

    Gender

    Pramipexole clearance is about 30% lower in women than in men, but this difference can be accounted for by differences in body weight. There is no difference in half-life between males and females.

    Age

    Pramipexole clearance decreases with age as the half-life and clearance are about 40% longer and 30% lower, respectively, in elderly (aged 65 years or older) compared with young healthy volunteers (aged less than 40 years). This difference is most likely due to the reduction in renal function with age, since pramipexole clearance is correlated with renal function, as measured by creatinine clearance.

    Race

    No racial differences in metabolism and elimination have been identified.

    Parkinson's Disease Patients

    A cross-study comparison of data suggests that the clearance of pramipexole may be reduced by about 30% in Parkinson's disease patients compared with healthy elderly volunteers. The reason for this difference appears to be reduced renal function in Parkinson's disease patients, which may be related to their poorer general health. The pharmacokinetics of pramipexole were comparable between early and advanced Parkinson's disease patients.

    Hepatic Impairment

    The influence of hepatic insufficiency on pramipexole pharmacokinetics has not been evaluated. Because approximately 90% of the recovered dose is excreted in the urine as unchanged drug, hepatic impairment would not be expected to have a significant effect on pramipexole elimination.

    Renal Impairment

    Clearance of pramipexole was about 75% lower in patients with severe renal impairment (creatinine clearance approximately 20 mL/min) and about 60% lower in patients with moderate impairment (creatinine clearance approximately 40 mL/min) compared with healthy volunteers [see Warnings and Precautions (5.6) and Dosage and Administration (2.2)]. In patients with varying degrees of renal impairment, pramipexole clearance correlates well with creatinine clearance. Therefore, creatinine clearance can be used as a predictor of the extent of decrease in pramipexole clearance.

    Drug Interactions

    Carbidopa/Levodopa

    Carbidopa/levodopa did not influence the pharmacokinetics of pramipexole in healthy volunteers (N = 10). Pramipexole did not alter the extent of absorption (AUC) or the elimination of carbidopa/levodopa, although it caused an increase in levodopa Cmax by about 40% and a decrease in Tmax from 2.5 to 0.5 hours.

    Selegiline

    In healthy volunteers (N = 11), selegiline did not influence the pharmacokinetics of pramipexole.

    Amantadine

    Population pharmacokinetic analyses suggest that amantadine may slightly decrease the oral clearance of pramipexole.

    Cimetidine

    Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N = 12).

    Probenecid

    Probenecid, a known inhibitor of renal tubular secretion of organic acids via the anionic transporter, did not noticeably influence pramipexole pharmacokinetics (N = 12).

    Other Drugs Eliminated Via Renal Secretion

    Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. Other known organic cation transport substrates and/or inhibitors (e.g., cisplatin and procainamide) may also decrease the clearance of pramipexole.

    CYP Interactions

    Inhibitors of cytochrome P450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro. Pramipexole does not inhibit CYP enzymes CYP1A2, CYP2C9, CYP2C19, CYP2E1, and CYP3A4. Inhibition of CYP2D6 was observed with an apparent Ki of 30 μM, indicating that pramipexole will not inhibit CYP enzymes at plasma concentrations observed following the clinical dose of 4.5 mg/day (1.5 mg TID).

    Close
  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Two-year carcinogenicity studies with pramipexole have been conducted in mice and rats. Pramipexole was administered in the diet to mice at doses up to 10 mg/kg/day (or approximately 10 times the maximum recommended human dose (MRHD) for Parkinson’s disease of 4.5 mg/day on a mg/m2 basis). Pramipexole was administered in the diet to rats at doses up to 8 mg/kg/day. These doses were associated with plasma AUCs up to approximately 12 times that in humans at the MRHD. No significant increases in tumors occurred in either species.

    Pramipexole was not mutagenic or clastogenic in a battery of in vitro (bacterial reverse mutation, V79/HGPRT gene mutation, chromosomal aberration in CHO cells) and in vivo (mouse micronucleus) assays.

    In rat fertility studies, pramipexole at a dose of 2.5 mg/kg/day (5 times the MRHD on a mg/m2 basis), prolonged estrus cycles and inhibited implantation. These effects were associated with reductions in serum levels of prolactin, a hormone necessary for implantation and maintenance of early pregnancy in rats.

    13.2 Animal Toxicology and/or Pharmacology

    Retinal Pathology in Rats

    Pathologic changes (degeneration and loss of photoreceptor cells) were observed in the retina of albino rats in the 2-year carcinogenicity study with pramipexole. These findings were first observed during week 76 and were dose-dependent in animals receiving 2 or 8 mg/kg/day (plasma AUCs equal to 2.5 and 12.5 times that in humans at the MRHD). In a similar study of pigmented rats with 2 years exposure to pramipexole at 2 or 8 mg/kg/day, retinal degeneration was not observed. Animals given drug had thinning in the outer nuclear layer of the retina that was only slightly greater (by morphometric analysis) than that seen in control rats.

    Investigative studies demonstrated that pramipexole reduced the rate of disk shedding from the photoreceptor rod cells of the retina in albino rats, which was associated with enhanced sensitivity to the damaging effects of light. In a comparative study, degeneration and loss of photoreceptor cells occurred in albino rats after 13 weeks of treatment with 25 mg/kg/day of pramipexole (54 times the MRHD on a mg/m2 basis) and constant light (100 lux) but not in pigmented rats exposed to the same dose and higher light intensities (500 lux). Thus, the retina of albino rats is considered to be uniquely sensitive to the damaging effects of pramipexole and light. Similar changes in the retina did not occur in a 2-year carcinogenicity study in albino mice treated with 0.3, 2, or 10 mg/kg/day (0.3, 2.2 and 11 times the MRHD on a mg/m2 basis). Evaluation of the retinas of monkeys given 0.1, 0.5, or 2 mg/kg/day of pramipexole (0.4, 2.2, and 8.6 times the MRHD on a mg/m2 basis) for 12 months and minipigs given 0.3, 1, or 5 mg/kg/day of pramipexole for 13 weeks also detected no changes.

    The potential significance of this effect in humans has not been established, but cannot be disregarded because disruption of a mechanism that is universally present in vertebrates (i.e., disk shedding) may be involved.

    Fibro-osseous Proliferative Lesions in Mice

    An increased incidence of fibro-osseous proliferative lesions occurred in the femurs of female mice treated for 2 years with 0.3, 2, or 10 mg/kg/day (0.3, 2.2, and 11 times the MRHD on a mg/m2 basis). Similar lesions were not observed in male mice or rats and monkeys of either sex that were treated chronically with pramipexole. The significance of this lesion to humans is not known.

    Close
  • 14 CLINICAL STUDIES

    14.1 Parkinson's Disease

    The effectiveness of pramipexole in the treatment of Parkinson's disease was evaluated in a multinational drug development program consisting of seven randomized, controlled trials. Three were conducted in patients with early Parkinson's disease who were not receiving concomitant levodopa, and four were conducted in patients with advanced Parkinson's disease who were receiving concomitant levodopa. Among these seven studies, three studies provide the most persuasive evidence of pramipexole's effectiveness in the management of patients with Parkinson's disease who were and were not receiving concomitant levodopa. Two of these three trials enrolled patients with early Parkinson's disease (not receiving levodopa), and one enrolled patients with advanced Parkinson's disease who were receiving maximally tolerated doses of levodopa.

    In all studies, the Unified Parkinson's Disease Rating Scale (UPDRS), or one or more of its subparts, served as the primary outcome assessment measure. The UPDRS is a four-part multi-item rating scale intended to evaluate mentation (part I), Activities of Daily Living (ADL) (part II), motor performance (part III), and complications of therapy (part IV).

    Part II of the UPDRS contains 13 questions relating to ADL, which are scored from 0 (normal) to 4 (maximal severity) for a maximum (worst) score of 52. Part III of the UPDRS contains 27 questions (for 14 items) and is scored as described for part II. It is designed to assess the severity of the cardinal motor findings in patients with Parkinson's disease (e.g., tremor, rigidity, bradykinesia, postural instability, etc.), scored for different body regions, and has a maximum (worst) score of 108.

    Studies in Patients with Early Parkinson's Disease

    Patients (N = 599) in the two studies of early Parkinson's disease had a mean disease duration of 2 years, limited or no prior exposure to levodopa (generally none in the preceding 6 months), and were not experiencing the "on-off" phenomenon and dyskinesia characteristic of later stages of the disease.

    One of the two early Parkinson's disease studies (N = 335) was a double-blind, placebo-controlled, parallel trial consisting of a 7-week dose-escalation period and a 6-month maintenance period. Patients could be on selegiline, anticholinergics, or both, but could not be on levodopa products or amantadine. Patients were randomized to pramipexole or placebo. Patients treated with pramipexole had a starting daily dose of 0.375 mg and were titrated to a maximally tolerated dose, but no higher than 4.5 mg/day in three divided doses. At the end of the 6-month maintenance period, the mean improvement from baseline on the UPDRS part II (ADL) total score was 1.9 in the group receiving pramipexole and -0.4 in the placebo group, a difference that was statistically significant. The mean improvement from baseline on the UPDRS part III total score was 5 in the group receiving pramipexole and -0.8 in the placebo group, a difference that was also statistically significant. A statistically significant difference between groups in favor of pramipexole was seen beginning at week 2 of the UPDRS part II (maximum dose 0.75 mg/day) and at week 3 of the UPDRS part III (maximum dose 1.5 mg/day).

    The second early Parkinson's disease study (N = 264) was a double-blind, placebo-controlled, parallel trial consisting of a 6-week dose-escalation period and a 4-week maintenance period. Patients could be on selegiline, anticholinergics, amantadine, or any combination of these, but could not be on levodopa products. Patients were randomized to 1 of 4 fixed doses of pramipexole (1.5 mg, 3 mg, 4.5 mg, or 6 mg per day) or placebo. At the end of the 4-week maintenance period, the mean improvement from baseline on the UPDRS part II total score was 1.8 in the patients treated with pramipexole, regardless of assigned dose group, and 0.3 in placebo-treated patients. The mean improvement from baseline on the UPDRS part III total score was 4.2 in patients treated with pramipexole and 0.6 in placebo-treated patients. No dose-response relationship was demonstrated. The between-treatment differences on both parts of the UPDRS were statistically significant in favor of pramipexole for all doses.

    No differences in effectiveness based on age or gender were detected. There were too few non-Caucasian patients to evaluate the effect of race. Patients receiving selegiline or anticholinergics had responses similar to patients not receiving these drugs.

    Studies in Patients with Advanced Parkinson's Disease

    In the advanced Parkinson's disease study, the primary assessments were the UPDRS and daily diaries that quantified amounts of "on" and "off" time.

    Patients in the advanced Parkinson's disease study (N = 360) had a mean disease duration of 9 years, had been exposed to levodopa for long periods of time (mean 8 years), used concomitant levodopa during the trial, and had "on-off" periods.

    The advanced Parkinson's disease study was a double-blind, placebo-controlled, parallel trial consisting of a 7-week dose-escalation period and a 6-month maintenance period. Patients were all treated with concomitant levodopa products and could additionally be on concomitant selegiline, anticholinergics, amantadine, or any combination. Patients treated with pramipexole had a starting dose of 0.375 mg/day and were titrated to a maximally tolerated dose, but no higher than 4.5 mg/day in three divided doses. At selected times during the 6-month maintenance period, patients were asked to record the amount of "off," "on," or "on with dyskinesia" time per day for several sequential days. At the end of the 6-month maintenance period, the mean improvement from baseline on the UPDRS part II total score was 2.7 in the group treated with pramipexole and 0.5 in the placebo group, a difference that was statistically significant. The mean improvement from baseline on the UPDRS part III total score was 5.6 in the group treated with pramipexole and 2.8 in the placebo group, a difference that was statistically significant. A statistically significant difference between groups in favor of pramipexole was seen at week 3 of the UPDRS part II (maximum dose 1.5 mg/day) and at week 2 of the UPDRS part III (maximum dose 0.75 mg/day). Dosage reduction of levodopa was allowed during this study if dyskinesia (or hallucinations) developed; levodopa dosage reduction occurred in 76% of patients treated with pramipexole vs. 54% of placebo patients. On average, the levodopa dose was reduced 27%.

    The mean number of "off" hours per day during baseline was 6 hours for both treatment groups. Throughout the trial, patients treated with pramipexole had a mean of 4 "off" hours per day, while placebo-treated patients continued to experience 6 "off" hours per day.

    No differences in effectiveness based on age or gender were detected. There were too few non-Caucasian patients to evaluate the effect of race.

    Close
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    Pramipexole Dihydrochloride Tablets are available as 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg or 1.5 mg tablets.

    The 0.125 mg tablets are white to off-white round, unscored tablets debossed with M on one side of the tablet and X4 on the other side. They are available as follows:

    NDC 0378-1704-60
    bottles of 63 tablets

    NDC 0378-1704-77
    bottles of 90 tablets

    NDC 0378-1704-05
    bottles of 500 tablets

    The 0.25 mg tablets are light orange round tablets debossed with M on one side of the tablet and X to the left of the score and 5 to the right of the score on the other side. They are available as follows:

    NDC 0378-1705-77
    bottles of 90 tablets

    NDC 0378-1705-05
    bottles of 500 tablets

    The 0.5 mg tablets are light blue round tablets debossed with M on one side of the tablet and X to the left of the score and 7 to the right of the score on the other side. They are available as follows:

    NDC 0378-1707-77
    bottles of 90 tablets

    NDC 0378-1707-05
    bottles of 500 tablets

    The 0.75 mg tablets are light gray round, unscored tablets debossed with M on one side of the tablet and X13 on the other side. They are available as follows:

    NDC 0378-1713-77
    bottles of 90 tablets

    NDC 0378-1713-05
    bottles of 500 tablets

    The 1 mg tablets are beige round tablets debossed with M on one side of the tablet and X to the left of the score and 11 to the right of the score on the other side. They are available as follows:

    NDC 0378-1711-77
    bottles of 90 tablets

    NDC 0378-1711-05
    bottles of 500 tablets

    The 1.5 mg tablets are light lavender round tablets debossed with M on one side of the tablet and X to the left of the score and 12 to the right of the score on the other side. They are available as follows:

    NDC 0378-1712-77
    bottles of 90 tablets

    NDC 0378-1712-05
    bottles of 500 tablets

    16.2 Storage and Handling

    Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

    Protect from light.

    Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

    PHARMACIST: Dispense a Patient Information Leaflet with each prescription.

    Close
  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling (Patient Information).

    Dosing Instructions

    Instruct patients to take pramipexole dihydrochloride tablets only as prescribed. If a dose is missed, advise patients not to double their next dose.

    Pramipexole dihydrochloride tablets can be taken with or without food. If patients develop nausea, advise that taking pramipexole dihydrochloride tablets with food may reduce the occurrence of nausea.

    Pramipexole is the active ingredient that is in both pramipexole dihydrochloride tablets and extended-release pramipexole tablets. Ensure that patients do not take both extended-release pramipexole and pramipexole dihydrochloride tablets.

    Sedating Effects

    Alert patients to the potential sedating effects associated with pramipexole dihydrochloride tablets, including somnolence and the possibility of falling asleep while engaged in activities of daily living. Since somnolence is a frequent adverse reaction with potentially serious consequences, patients should neither drive a car nor engage in other potentially dangerous activities until they have gained sufficient experience with pramipexole dihydrochloride tablets to gauge whether or not it affects their mental and/or motor performance adversely. Advise patients that if increased somnolence or new episodes of falling asleep during activities of daily living (e.g., conversations or eating) are experienced at any time during treatment, they should not drive or participate in potentially dangerous activities until they have contacted their physician. Because of possible additive effects, advise caution when patients are taking other sedating medications or alcohol in combination with pramipexole dihydrochloride tablets and when taking concomitant medications that increase plasma levels of pramipexole (e.g., cimetidine) [see Warnings and Precautions (5.1)].

    Impulse Control Symptoms Including Compulsive Behaviors

    Alert patients and their caregivers to the possibility that they may experience intense urges to spend money uncontrollably, intense urges to gamble, increased sexual urges, binge eating and/or other intense urges and the inability to control these urges while taking pramipexole dihydrochloride tablets [see Warnings and Precautions (5.3)].

    Hallucinations and Psychotic-like Behavior

    Inform patients that hallucinations and other psychotic-like behavior can occur and that the elderly are at a higher risk than younger patients with Parkinson's disease [see Warnings and Precautions (5.4)].

    Postural (Orthostatic) Hypotension

    Advise patients that they may develop postural (orthostatic) hypotension, with or without symptoms such as dizziness, nausea, fainting or blackouts, and sometimes, sweating. Hypotension may occur more frequently during initial therapy. Accordingly, caution patients against rising rapidly after sitting or lying down, especially if they have been doing so for prolonged periods and especially at the initiation of treatment with pramipexole dihydrochloride tablets [see Warnings and Precautions (5.2)].

    Pregnancy

    Because the teratogenic potential of pramipexole has not been completely established in laboratory animals, and because experience in humans is limited, advise women to notify their physicians if they become pregnant or intend to become pregnant during therapy [see Use in Specific Populations (8.1)].

    Nursing Mothers

    Because of the possibility that pramipexole may be excreted in breast milk, advise women to notify their physicians if they intend to breast-feed or are breast-feeding an infant [see Use in Specific Populations (8.3)].

    Close
  •         

    PATIENT INFORMATION LEAFLET
    PRAMIPEXOLE DIHYDROCHLORIDE TABLETS
    (pram'' i pex' ole dye hye'' droe klor' ide)

    0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg and 1.5 mg

    Read this Patient Information before you start taking pramipexole dihydrochloride tablets and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.

    What are pramipexole dihydrochloride tablets?

    Pramipexole dihydrochloride tablets are a prescription medicine used to treat:

    signs and symptoms of Parkinson's disease (PD)

    It is not known if pramipexole dihydrochloride tablets are safe and effective in children.

    What should I tell my doctor before taking pramipexole dihydrochloride tablets?

    Before taking pramipexole dihydrochloride tablets, tell your doctor if you:
    feel sleepy during the day from a sleep problem
    have low blood pressure, or if you feel dizzy or faint, especially when getting up from sitting or lying down
    have trouble controlling your muscles (dyskinesia)
    have kidney problems
    drink alcohol. Alcohol can increase the chance that pramipexole dihydrochloride tablets will make you feel sleepy or fall asleep when you should be awake.
    have any other medical conditions
    are pregnant or plan to become pregnant. It is not known if pramipexole dihydrochloride tablets will harm your unborn baby.
    are breastfeeding or plan to breastfeed. It is not known if pramipexole dihydrochloride passes into your breast milk. You and your doctor should decide if you will take pramipexole dihydrochloride tablets or breastfeed. You should not do both.

    Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

    The combination of pramipexole dihydrochloride tablets and other medicines may affect each other and may cause side effects. Pramipexole dihydrochloride tablets may affect the way other medicines work, and other medicines may affect how pramipexole dihydrochloride tablets work.

    Especially tell your doctor if you take:

    medicines called neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide. Pramipexole dihydrochloride tablets may not work as well if you take these medicines.
    pramipexole dihydrochloride extended-release tablets. Pramipexole is the active ingredient in both pramipexole dihydrochloride tablets and pramipexole dihydrochloride extended-relase tablets. If you are taking pramipexole dihydrochloride extended-release tablets, you should not take pramipexole dihydrochloride tablets.
    any other medicines that make you sleepy or may increase the effects of pramipexole dihydrochloride tablets, such as cimetidine (Tagamet*).

    Ask your doctor for a list of these medicines if you are not sure.

    Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.

    How should I take pramipexole dihydrochloride tablets?

    Take pramipexole dihydrochloride tablets exactly as your doctor tells you to take it.
    Your doctor will tell you how many pramipexole dihydrochloride tablets to take and when to take it. Do not take more or less pramipexole dihydrochloride tablets than your doctor tells you to.
    Your doctor may change your dose if needed.
    Pramipexole dihydrochloride tablets can be taken with or without food. Taking pramipexole dihydrochloride tablets with food may lower your chances of getting nausea.
    If you take more pramipexole dihydrochloride tablets than your doctor recommends, call your doctor or go to the nearest hospital emergency room right away.
    If you miss a dose, do not double your next dose. Skip the dose you missed and take your next regular dose.
    If you have Parkinson’s disease and your doctor tells you to stop taking pramipexole dihydrochloride tablets, you should stop pramipexole dihydrochloride tablets slowly as directed by your doctor. If you stop pramipexole dihydrochloride tablets too quickly you may have withdrawal symptoms such as:
    fever
    confusion
    severe muscle stiffness
     
    Do not stop taking pramipexole dihydrochloride tablets without talking to your doctor.

    What should I avoid while taking pramipexole dihydrochloride tablets?

    Do not drink alcohol while taking pramipexole dihydrochloride tablets. It can increase your chance of having serious side effects. See “What are the possible side effects of pramipexole dihydrochloride tablets?”
    Do not drive a car, operate a machine, or do other dangerous activities until you know how pramipexole dihydrochloride tablets affect you. Sleepiness caused by pramipexole dihydrochloride tablets can happen as late as one year after you start your treatment.

    What are the possible side effects of pramipexole dihydrochloride tablets?

    Pramipexole dihydrochloride tablets may cause serious side effects, including:

    falling asleep during normal daily activities. Pramipexole dihydrochloride tablets may cause you to fall asleep while you are doing daily activities such as driving, talking with other people, or eating.
    Some people taking the medicine in pramipexole dihydrochloride tablets have had car accidents because they fell asleep while driving.
    Some patients did not feel sleepy before they fell asleep while driving. You could fall asleep without any warning.
     
    Tell your doctor right away if you fall asleep while you are doing activities such as talking, eating, driving, or if you feel sleepier than normal for you.
    low blood pressure when you sit or stand up quickly. You may have:
    dizziness
    nausea
    fainting
    sweating
     
    Sit and stand up slowly after you have been sitting or lying down.
    unusual urges. Some people who take certain medicines to treat Parkinson’s disease, including pramipexole dihydrochloride tablets, have reported problems, such as gambling, compulsive eating, compulsive buying, and increased sex drive. If you or your family members notice that you are developing unusual urges or behaviors, talk to your doctor.
    hallucinations and other psychotic-like behavior (seeing visions, hearing sounds or feeling sensations that are not real, confusion, excessive suspicion, aggressive behavior, agitation, delusional beliefs and disorganized thinking). Your chance of having hallucinations and other psychotic-like behavior is higher if you are elderly (age 65 or older). If you have hallucinations or other psychotic-like changes, talk with your doctor right away.
    uncontrolled sudden movements (dyskinesia) . If you have new dyskinesia or your existing dyskinesia gets worse tell your doctor.
    skin cancer (melanoma). Some people with Parkinson’s disease may have a higher chance of having melanoma than people who do not have Parkinson’s disease. It is not known if the chance of having melanoma is higher because of the medicines to treat Parkinson’s disease, like pramipexole dihydrochloride tablets, or from the Parkinson’s disease. People who take pramipexole dihydrochloride tablets should have regular skin examinations to check for melanoma.

    The most common side effects in people taking pramipexole dihydrochloride tablets for Parkinson’s disease are:

    nausea
    dizziness
    insomnia
    constipation
    muscle weakness
    abnormal dreams
    confusion
    memory problems (amnesia)
    urinating more often than normal

    These are not all the possible side effects of pramipexole dihydrochloride tablets. Tell your doctor if you have any side effect that bothers you.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    How should I store pramipexole dihydrochloride tablets?

    Store pramipexole dihydrochloride tablets at 20° to 25°C (68° to 77°F).
    Protect from light.
    Keep pramipexole dihydrochloride tablets and all medicines out of the reach of children.

    General Information about the safe and effective use of pramipexole dihydrochloride tablets.

    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use pramipexole dihydrochloride tablets for a condition for which it was not prescribed. Do not give pramipexole dihydrochloride tablets to other people, even if they have the same symptoms that you have. It may harm them.

    This Patient Information leaflet summarizes the most important information about pramipexole dihydrochloride tablets. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about pramipexole dihydrochloride tablets that is written for healthcare professionals.

    For more information, call Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX).

    What are the ingredients in pramipexole dihydrochloride tablets?

    Active Ingredient: pramipexole dihydrochloride, USP

    Inactive Ingredients: colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, magnesium stearate, mannitol, pregelatinized starch (corn) and sodium citrate. In addition, the following product specific coloring agents are present: 0.25 mg contains FD&C Yellow No. 6 Aluminum Lake; 0.5 mg contains FD&C Yellow No. 6 Aluminum Lake and FD&C Blue No. 2 Aluminum Lake; 0.75 mg contains FD&C Yellow No. 6 Aluminum Lake and FD&C Blue No. 2 Aluminum Lake; 1 mg contains FD&C Yellow No. 6 Aluminum Lake and FD&C Blue No. 2 Aluminum Lake; 1.5 mg contains FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake and D&C Red No. 27 Aluminum Lake.

    This Patient Information has been approved by the U.S. Food and Drug Administration.

    *The brands listed are trademarks of their respective owners.

    Mylan Pharmaceuticals Inc.
    Morgantown, WV 26505 U.S.A.

    REVISED: APRIL 2015
    PRMX:R6ppbpt

    Close
  •          

    PRINCIPAL DISPLAY PANEL - 0.125 mg

    NDC 0378-1704-60

    Pramipexole
    Dihydrochloride
    Tablets
    0.125 mg

    PHARMACIST: Dispense the accompanying
    Patient Information Leaflet to each patient.

    Rx only     63 Tablets

    Each tablet contains:
    Pramipexole dihydrochloride
    monohydrate 0.125 mg

    Dispense in a tight, light-resistant
    container as defined in the USP
    using a child-resistant closure.

    Keep container tightly closed.

    Keep this and all medication
    out of the reach of children.

    Store at 20° to 25°C (68° to 77°F).
    [See USP Controlled Room
    Temperature.]

    Protect from light.

    Usual Dosage: See accompanying
    prescribing information.

    Mylan Pharmaceuticals Inc.
    Morgantown, WV 26505 U.S.A.

    Mylan.com

    RM1704CS3

    Pramipexole Dihydrochloride Tablets 0.125 mg Bottle Label
    Close
  •          

    PRINCIPAL DISPLAY PANEL - 0.25 mg

    NDC 0378-1705-77

    Pramipexole
    Dihydrochloride
    Tablets
    0.25 mg

    PHARMACIST: Dispense the accompanying
    Patient Information Leaflet to each patient.

    Rx only     90 Tablets

    Each tablet contains:
    Pramipexole dihydrochloride
    monohydrate 0.25 mg

    Dispense in a tight, light-resistant
    container as defined in the USP
    using a child-resistant closure.

    Keep container tightly closed.

    Keep this and all medication
    out of the reach of children.

    Store at 20° to 25°C (68° to 77°F).
    [See USP Controlled Room
    Temperature.]

    Protect from light.

    Usual Dosage: See accompanying
    prescribing information.

    Mylan Pharmaceuticals Inc.
    Morgantown, WV 26505 U.S.A.

    Mylan.com

    RM1705MM3

    Pramipexole Dihydrochloride Tablets 0.25 mg Bottle Label
    Close
  •      

    PRINCIPAL DISPLAY PANEL - 0.5 mg

    NDC 0378-1707-77

    Pramipexole
    Dihydrochloride
    Tablets
    0.5 mg

    PHARMACIST: Dispense the accompanying
    Patient Information Leaflet to each patient.

    Rx only     90 Tablets

    Each tablet contains:
    Pramipexole dihydrochloride
    monohydrate 0.5 mg

    Dispense in a tight, light-resistant
    container as defined in the USP
    using a child-resistant closure.

    Keep container tightly closed.

    Keep this and all medication
    out of the reach of children.

    Store at 20° to 25°C (68° to 77°F).
    [See USP Controlled Room
    Temperature.]

    Protect from light.

    Usual Dosage: See accompanying
    prescribing information.

    Mylan Pharmaceuticals Inc.
    Morgantown, WV 26505 U.S.A.

    Mylan.com

    RM1707MM3

    Pramipexole Dihydrochloride Tablets 0.5 mg Bottle Label
    Close
  •           

    PRINCIPAL DISPLAY PANEL - 0.75 mg

    NDC 0378-1713-77

    Pramipexole
    Dihydrochloride
    Tablets
    0.75 mg

    PHARMACIST: Dispense the accompanying
    Patient Information Leaflet to each patient.

    Rx only     90 Tablets

    Each tablet contains:
    Pramipexole dihydrochloride
    monohydrate 0.75 mg

    Dispense in a tight, light-resistant
    container as defined in the USP
    using a child-resistant closure.

    Keep container tightly closed.

    Keep this and all medication
    out of the reach of children.

    Store at 20° to 25°C (68° to 77°F).
    [See USP Controlled Room
    Temperature.]

    Protect from light.

    Usual Dosage: See accompanying
    prescribing information.

    Mylan Pharmaceuticals Inc.
    Morgantown, WV 26505 U.S.A.

    Mylan.com

    RM1713MM4

    Pramipexole Dihydrochloride Tablets 0.75 mg Bottle Label
    Close
  •            

    PRINCIPAL DISPLAY PANEL - 1 mg

    NDC 0378-1711-77

    Pramipexole
    Dihydrochloride
    Tablets
    1 mg

    PHARMACIST: Dispense the accompanying
    Patient Information Leaflet to each patient.

    Rx only     90 Tablets

    Each tablet contains:
    Pramipexole dihydrochloride
    monohydrate 1 mg

    Dispense in a tight, light-resistant
    container as defined in the USP
    using a child-resistant closure.

    Keep container tightly closed.

    Keep this and all medication
    out of the reach of children.

    Store at 20° to 25°C (68° to 77°F).
    [See USP Controlled Room
    Temperature.]

    Protect from light.

    Usual Dosage: See accompanying
    prescribing information.

    Mylan Pharmaceuticals Inc.
    Morgantown, WV 26505 U.S.A.

    Mylan.com

    RM1711MM3

    Pramipexole Dihydrochloride Tablets 1 mg Bottle Label
    Close
  •           

    PRINCIPAL DISPLAY PANEL – 1.5 mg

    NDC 0378-1712-77

    Pramipexole
    Dihydrochloride
    Tablets
    1.5 mg

    PHARMACIST: Dispense the accompanying
    Patient Information Leaflet to each patient.

    Rx only     90 Tablets

    Each tablet contains:
    Pramipexole dihydrochloride
    monohydrate 1.5 mg

    Dispense in a tight, light-resistant
    container as defined in the USP
    using a child-resistant closure.

    Keep container tightly closed.

    Keep this and all medication
    out of the reach of children.

    Store at 20° to 25°C (68° to 77°F).
    [See USP Controlled Room
    Temperature.]

    Protect from light.

    Usual Dosage: See accompanying
    prescribing information.

    Mylan Pharmaceuticals Inc.
    Morgantown, WV 26505 U.S.A.

    Mylan.com

    RM1712MM3

    Pramipexole Dihydrochloride Tablets 1.5 mg Bottle Label
    Close
  • INGREDIENTS AND APPEARANCE
    PRAMIPEXOLE DIHYDROCHLORIDE 
    pramipexole dihydrochloride tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0378-1704
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    PRAMIPEXOLE DIHYDROCHLORIDE (UNII: 3D867NP06J) (PRAMIPEXOLE - UNII:83619PEU5T) PRAMIPEXOLE DIHYDROCHLORIDE 0.125 mg
    Inactive Ingredients
    Ingredient Name Strength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSPOVIDONE (UNII: 68401960MK)  
    HYDROXYPROPYL CELLULOSE (TYPE H) (UNII: RFW2ET671P)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    SODIUM CITRATE (UNII: 1Q73Q2JULR)  
    Product Characteristics
    Color WHITE (white to off-white) Score no score
    Shape ROUND Size 6mm
    Flavor Imprint Code M;X4
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0378-1704-60 63 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    2 NDC:0378-1704-77 90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    3 NDC:0378-1704-05 500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA077854 11/04/2010
    PRAMIPEXOLE DIHYDROCHLORIDE 
    pramipexole dihydrochloride tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0378-1705
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    PRAMIPEXOLE DIHYDROCHLORIDE (UNII: 3D867NP06J) (PRAMIPEXOLE - UNII:83619PEU5T) PRAMIPEXOLE DIHYDROCHLORIDE 0.25 mg
    Inactive Ingredients
    Ingredient Name Strength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSPOVIDONE (UNII: 68401960MK)  
    HYDROXYPROPYL CELLULOSE (TYPE H) (UNII: RFW2ET671P)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    SODIUM CITRATE (UNII: 1Q73Q2JULR)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    Product Characteristics
    Color ORANGE (light orange) Score 2 pieces
    Shape ROUND Size 6mm
    Flavor Imprint Code M;X;5
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0378-1705-77 90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    2 NDC:0378-1705-05 500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA077854 11/04/2010
    PRAMIPEXOLE DIHYDROCHLORIDE 
    pramipexole dihydrochloride tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0378-1707
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    PRAMIPEXOLE DIHYDROCHLORIDE (UNII: 3D867NP06J) (PRAMIPEXOLE - UNII:83619PEU5T) PRAMIPEXOLE DIHYDROCHLORIDE 0.5 mg
    Inactive Ingredients
    Ingredient Name Strength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSPOVIDONE (UNII: 68401960MK)  
    HYDROXYPROPYL CELLULOSE (TYPE H) (UNII: RFW2ET671P)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    SODIUM CITRATE (UNII: 1Q73Q2JULR)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    FD&C BLUE NO. 2 (UNII: L06K8R7DQK)  
    Product Characteristics
    Color BLUE (light blue) Score 2 pieces
    Shape ROUND Size 6mm
    Flavor Imprint Code M;X;7
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0378-1707-77 90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    2 NDC:0378-1707-05 500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA077854 11/04/2010
    PRAMIPEXOLE DIHYDROCHLORIDE 
    pramipexole dihydrochloride tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0378-1713
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    PRAMIPEXOLE DIHYDROCHLORIDE (UNII: 3D867NP06J) (PRAMIPEXOLE - UNII:83619PEU5T) PRAMIPEXOLE DIHYDROCHLORIDE 0.75 mg
    Inactive Ingredients
    Ingredient Name Strength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSPOVIDONE (UNII: 68401960MK)  
    HYDROXYPROPYL CELLULOSE (TYPE H) (UNII: RFW2ET671P)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    SODIUM CITRATE (UNII: 1Q73Q2JULR)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    FD&C BLUE NO. 2 (UNII: L06K8R7DQK)  
    Product Characteristics
    Color GRAY (light gray) Score no score
    Shape ROUND Size 7mm
    Flavor Imprint Code M;X13
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0378-1713-77 90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    2 NDC:0378-1713-05 500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA090764 11/04/2010
    PRAMIPEXOLE DIHYDROCHLORIDE 
    pramipexole dihydrochloride tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0378-1711
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    PRAMIPEXOLE DIHYDROCHLORIDE (UNII: 3D867NP06J) (PRAMIPEXOLE - UNII:83619PEU5T) PRAMIPEXOLE DIHYDROCHLORIDE 1 mg
    Inactive Ingredients
    Ingredient Name Strength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSPOVIDONE (UNII: 68401960MK)  
    HYDROXYPROPYL CELLULOSE (TYPE H) (UNII: RFW2ET671P)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    SODIUM CITRATE (UNII: 1Q73Q2JULR)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    FD&C BLUE NO. 2 (UNII: L06K8R7DQK)  
    Product Characteristics
    Color WHITE (beige) Score 2 pieces
    Shape ROUND Size 8mm
    Flavor Imprint Code M;X;11
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0378-1711-77 90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    2 NDC:0378-1711-05 500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA077854 11/04/2010
    PRAMIPEXOLE DIHYDROCHLORIDE 
    pramipexole dihydrochloride tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0378-1712
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    PRAMIPEXOLE DIHYDROCHLORIDE (UNII: 3D867NP06J) (PRAMIPEXOLE - UNII:83619PEU5T) PRAMIPEXOLE DIHYDROCHLORIDE 1.5 mg
    Inactive Ingredients
    Ingredient Name Strength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    CROSPOVIDONE (UNII: 68401960MK)  
    HYDROXYPROPYL CELLULOSE (TYPE H) (UNII: RFW2ET671P)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    MANNITOL (UNII: 3OWL53L36A)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    SODIUM CITRATE (UNII: 1Q73Q2JULR)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    FD&C BLUE NO. 2 (UNII: L06K8R7DQK)  
    D&C RED NO. 27 (UNII: 2LRS185U6K)  
    Product Characteristics
    Color PURPLE (light lavender) Score 2 pieces
    Shape ROUND Size 10mm
    Flavor Imprint Code M;X;12
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0378-1712-77 90 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    2 NDC:0378-1712-05 500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA077854 11/04/2010
    Labeler - Mylan Pharmaceuticals Inc. (059295980)
    Close